SCHEMBL2196435

SCHEMBL2196435

Brc1ccc(CN(I)I)cc1.[Pt]=c1[nH]c(Cc2ccccc2)nn1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 2/20 0.39
GALR3 O60755 1/20 0.39
NPY1R P25929 1/20 0.39
STAT3 P40763 1/20 0.39
NPY2R P49146 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
ALDH1A1 P00352 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 2/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.33
GRM2 Q14416 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194665 0.93 KDM4E (0.38) MEN1KMT2AGAANR1H3ALDH1A1
SCHEMBL2195682 0.90 SMN1; SMN2 (0.39) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL2198381 0.90 LMNA (0.39) MEN1KMT2AGAAMAPTSTAT3
SCHEMBL2197397 0.89 CACNA1G (0.38) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL2195871 0.86 CXCR2 (0.37) NR1H2NR1H3SMN1; SMN2
SCHEMBL2194436 0.85 BCHE (0.34) MEN1KMT2AGAAMAPTGALR3
SCHEMBL2196581 0.78 HSD17B10 (0.36) MEN1KMT2AGAAMAPTNR1H3
SCHEMBL2195699 0.78 HSD17B10 (0.35) MEN1KMT2AGAAMAPTNR1H3
SCHEMBL2195930 0.77 GAA (0.34) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL2192152 0.77 HSD17B10 (0.38) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MEN1 766/4885KMT2A 4286/4885GAA 4532/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MEN1 766/4885KMT2A 4286/4885GAA 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.